Michael Shlipak, MD, MPH


Dr. Shlipak is a Co-Founder and Scientific Director of the KHRC. He is also the Associate Chief of Medicine for Research at the San Francisco VA Medical Center and a Professor of Medicine at the University of California, San Francisco School of Medicine. He graduated from Harvard Medical School and obtained his MPH from the Harvard School of Public Health. He completed internal medicine residency and a General Internal Medicine fellowship at UCSF. His research missions include the prevention of chronic kidney disease and its complications, and the development of investigators in clinical research. His research activities involve the detection and the determinants of kidney disease, and its association with adverse outcomes, including cardiovascular disease. He has been particularly focused on the use of cystatin C as a novel indicator of kidney function and its potential to improve understanding of kidney disease epidemiology and clinical care. He is the author of over 500 peer-reviewed manuscripts and was 1 of 16 co-authors for the 2013 KDIGO Guidelines on Definition and Classification of Chronic Kidney Disease. He recently Chaired the 2019 KDIGO Controversies Conference on CKD Detection, Risk Stratification and Treatment that concluded with recommendations for screening of persons with diabetes, hypertension, or cardiovascular disease with the combination of creatinine, cystatin C, and albuminuria testing.  Dr. Shlipak’s research has been continuously funded by NIH grants for the past 21 years, in addition to research grants from the Veterans Affairs Health Services Research and Development Service, Robert Wood Johnson Foundation, the American Heart Association, and the American Federation for Aging Research.

You can see Dr. Shlipak's complete faculty profile here.